195 related articles for article (PubMed ID: 18027989)
21. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma.
Toffoli G; Corona G; Cattarossi G; Boiocchi M; Di Gennaro G; Tirelli U; Vaccher E
Ann Oncol; 2004 Dec; 15(12):1805-9. PubMed ID: 15550586
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.
Doyle JJ; Neugut AI; Jacobson JS; Grann VR; Hershman DL
J Clin Oncol; 2005 Dec; 23(34):8597-605. PubMed ID: 16314622
[TBL] [Abstract][Full Text] [Related]
23. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer.
Dees EC; O'Reilly S; Goodman SN; Sartorius S; Levine MA; Jones RJ; Grochow LB; Donehower RC; Fetting JH
Cancer Invest; 2000; 18(6):521-9. PubMed ID: 10923100
[TBL] [Abstract][Full Text] [Related]
24. Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients.
Ahmed JH; Makonnen E; Bisaso RK; Mukonzo JK; Fotoohi A; Aseffa A; Howe R; Hassan M; Aklillu E
Front Pharmacol; 2020; 11():406. PubMed ID: 32390827
[TBL] [Abstract][Full Text] [Related]
25. Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP.
Baudry E; Huguet S; Couderc AL; Chaibi P; Bret F; Verny C; Weill S; Madar O; Urien S; Rezai K
Cancer Chemother Pharmacol; 2019 Apr; 83(4):775-785. PubMed ID: 30689002
[TBL] [Abstract][Full Text] [Related]
26. Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers.
Wittenburg LA; Weishaar K; Ramirez D; Gustafson DL
Vet Comp Oncol; 2019 Jun; 17(2):147-154. PubMed ID: 30638304
[TBL] [Abstract][Full Text] [Related]
27. Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study.
Giotta F; Lorusso V; Maiello E; Filippelli G; Valerio MR; Caruso M; Verderame F; Latorre A; Colucci G
Ann Oncol; 2007 Jun; 18 Suppl 6():vi66-9. PubMed ID: 17591836
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
Danesi R; Innocenti F; Fogli S; Gennari A; Baldini E; Di Paolo A; Salvadori B; Bocci G; Conte PF; Del Tacca M
Br J Clin Pharmacol; 2002 May; 53(5):508-18. PubMed ID: 11994057
[TBL] [Abstract][Full Text] [Related]
29. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.
Lal S; Sandanaraj E; Wong ZW; Ang PC; Wong NS; Lee EJ; Chowbay B
Cancer Sci; 2008 Oct; 99(10):2045-54. PubMed ID: 19016765
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
Joerger M; Huitema AD; Richel DJ; Dittrich C; Pavlidis N; Briasoulis E; Vermorken JB; Strocchi E; Martoni A; Sorio R; Sleeboom HP; Izquierdo MA; Jodrell DI; Calvert H; Boddy AV; Hollema H; Féty R; Van der Vijgh WJ; Hempel G; Chatelut E; Karlsson M; Wilkins J; Tranchand B; Schrijvers AH; Twelves C; Beijnen JH; Schellens JH
Clin Cancer Res; 2007 Nov; 13(21):6410-8. PubMed ID: 17975154
[TBL] [Abstract][Full Text] [Related]
31. Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®).
Boers-Sonderen MJ; van Herpen CM; van der Graaf WT; Desar IM; van der Logt MG; de Beer YM; Ottevanger PB; van Erp NP
Cancer Chemother Pharmacol; 2014 Sep; 74(3):457-63. PubMed ID: 24965180
[TBL] [Abstract][Full Text] [Related]
32. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide.
Hesketh PJ; Gandara DR; Hesketh AM; Facada A; Perez EA; Webber LM; Martin LA; Cramer MB; Hahne WF
Support Care Cancer; 1996 Mar; 4(2):141-6. PubMed ID: 8673351
[TBL] [Abstract][Full Text] [Related]
33. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer.
Rushing DA; Raber SR; Rodvold KA; Piscitelli SC; Plank GS; Tewksbury DA
Cancer; 1994 Aug; 74(3):834-41. PubMed ID: 8039111
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
35. A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies.
Lopez AM; Ketchum M; Nichols H; Xu MJ; Peng YM; Dorr R; Alberts DS
Cancer Chemother Pharmacol; 2000; 46(5):411-5. PubMed ID: 11127946
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Chan S
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy for advanced breast cancer: cyclophosphamide, doxorubicin, UFT, and tamoxifen.
Fukuda M; Yamaguchi S; Ohta T; Nakayama Y; Ogata H; Shimizu K; Nishikawa T; Adachi Y; Fukuma E
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):77-81. PubMed ID: 10442369
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics and pharmacodynamics of oral etoposide.
Toffoli G; Corona G; Sorio R; Robieux I; Basso B; Colussi AM; Boiocchi M
Br J Clin Pharmacol; 2001 Nov; 52(5):511-9. PubMed ID: 11736859
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer.
Fleming GF; Waggoner SE; Rotmensch J; Skoog LA; Langhauser C
Gynecol Oncol; 1997 Apr; 65(1):42-5. PubMed ID: 9103389
[TBL] [Abstract][Full Text] [Related]
40. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.
de Jonge ME; Huitema AD; Beijnen JH; Rodenhuis S
Br J Cancer; 2006 May; 94(9):1226-30. PubMed ID: 16622453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
